Innovative use of therapeutic antibodies in lung cancer: the current landscape of ADCs and other antibody-based therapies.

The therapeutic landscape for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) has been profoundly transformed by the advent of novel antibody therapies. These include antibody-drug conjugates (ADCs) and various novel iterations. Each therapy is at a different stage of clinical development, with several agents now approved for clinical use, others in late-stage trials, and a robust pipeline of preclinical candidates. This review will provide an overview of the antibody-based therapies, focusing on their molecular targets and clinical context in lung cancer and the future of this rapidly emerging field.